A Phase 2, 12-week, Adaptive, Open Label, Sequential Cohort Trial To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of Pf-06730512 Following Multiple Doses In Adult Subjects With Primary Focal Segmental Glomerulosclerosis (Fsgs)
Phase of Trial: Phase II
Latest Information Update: 19 Aug 2018
At a glance
- Drugs PF-06730512 (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Therapeutic Use
- Sponsors Pfizer
- 27 Jul 2018 Planned End Date changed from 12 Apr 2021 to 7 May 2021.
- 27 Jul 2018 Planned primary completion date changed from 12 Apr 2021 to 7 May 2021.
- 02 Jul 2018 Planned End Date changed from 16 Mar 2021 to 12 Apr 2021.